How Genetic Testing Can Help Predict Opioid Use Disorder Risk

Opioid Use Disorder Risk

AvertD is an FDA-approved genetic test that uses advanced scientific techniques to identify individuals at higher genetic risk for developing opioid use disorder (OUD)1. By analyzing DNA, the test detects 15 specific genetic polymorphisms that may be linked to an increased susceptibility to OUD, including variations in genes related to serotonin, dopamine, and opioid receptors […]

NELC 2024: Don’t Miss Out on the Premier Laboratory Education Innovation Event

NELC 2024

With the Northeast Laboratory Conference (NELC) 2024 just around the corner, the excitement is building! Scheduled for October 15th – 16th at Holiday Inn by the Bay (88 Spring Street Portland, Maine), this premier event is the must-attend gathering for educators, technologists, and education leaders who are passionate about laboratory sciences and services. As the […]

LCMS Testing of Xylazine

LCMS Testing of Xylazine

Xylazine, an approved animal tranquilizer in the U.S., acts as a sedative and analgesic for veterinary use [1]. It is an α-2 adrenoreceptor agonist, detected in the unregulated drug supply throughout the eastern United States and Canada [2]. It has been detected in 91% of fentanyl/ heroin samples in Philadelphia and showed its presence in national […]

Fentanyl Immunoassay is a Vital Tool in the Battle Against Opioid Crisis

Fentanyl Immunoassay

Fentanyl is a synthetic opioid that is 50 to 100 times more potent than morphine. It is used to treat patients with severe pain after surgery, especially those who are physically tolerant to other opioids [1]. However, it is often abused illegally and mixed with other drugs, which can result in dangerous respiratory depression. The […]